Literature DB >> 27609535

Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

Emilande Guichet1, Avelin Aghokeng2, Sabrina Eymard-Duvernay1, Nicole Vidal1, Ahidjo Ayouba1, Eitel Mpoudi Ngole3, Eric Delaporte1, Laura Ciaffi1, Martine Peeters4.   

Abstract

With the increasing demand of HIV viral load (VL) tests in resource-limited countries (RLCs) there is a need for assays at affordable cost and able to quantify all known HIV-1 variants. VLs obtained with a recently developed open and polyvalent universal HIV-1/SIVcpz/SIVgor RT-qPCR were compared to Abbott RealTime HIV-1 assay in Cameroon. On 474 plasma samples, characterized by a wide range of VLs and a broad HIV-1 group M genetic diversity, 97.5% concordance was observed when using the lower detection limit of each assay. When using the threshold of 3.00 log10 copies/mL, according to WHO guidelines to define virological failure (VF) in RLCs, the concordance was 94.7%, 360/474 versus 339/474 patients were identified with VF with the new assay and Abbott RealTime HIV-1, respectively. Higher VLs were measured with the new assay, +0.47 log10 copies/mL (95% CI; 0.42-0.52) as shown with Bland-Altman analysis. Eleven samples from patients on VF with drug resistance were not detected by Abbott RealTime HIV-1 versus two only with the new assay. Overall, our study showed that the new assay can be easily implemented in a laboratory in RLCs with VL experience and showed good performance on a wide diversity of HIV-1 group M variants.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Africa; Genetic diversity; HIV-1; Subtype; Viral load

Mesh:

Substances:

Year:  2016        PMID: 27609535      PMCID: PMC5301037          DOI: 10.1016/j.jviromet.2016.09.005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  34 in total

1.  Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.

Authors:  Peilin Li; Theodore Ruel; Katsuya Fujimoto; Hiroyu Hatano; Steven Yukl; Leigh Anne Eller; Teri Liegler; Moses Kamya; Anne Gassasira; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2010-09-21       Impact factor: 2.014

2.  Comparison of the bioMérieux NucliSENS EasyQ HIV-1 v2.0-HIV-1 RNA quantification assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants.

Authors:  Thomas Mourez; Constance Delaugerre; Muriel Vray; Véronique Lemée; François Simon; Jean-Christophe Plantier
Journal:  J Clin Virol       Date:  2015-08-18       Impact factor: 3.168

Review 3.  HIV-1 viral load testing cost in developing countries: what's new?

Authors:  François Rouet; Christine Rouzioux
Journal:  Expert Rev Mol Diagn       Date:  2007-11       Impact factor: 5.225

4.  Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.

Authors:  François Rouet; Marie-Laure Chaix; Eric Nerrienet; Nicole Ngo-Giang-Huong; Jean-Christophe Plantier; Marianne Burgard; Martine Peeters; Florence Damond; Didier Koumavi Ekouevi; Philippe Msellati; Laurent Ferradini; Sandra Rukobo; Valérie Maréchal; Nilda Schvachsa; Lahcen Wakrim; Christian Rafalimanana; Benjamin Rakotoambinina; Jean-Paul Viard; Jean-Marie Seigneurin; Christine Rouzioux
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

Review 5.  Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

Authors:  Kathryn M Stadeli; Douglas D Richman
Journal:  Antivir Ther       Date:  2012-10-10

6.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

7.  HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Authors:  Christian Julian Villabona-Arenas; Jenny Domyeum; Fatima Mouacha; Christelle Butel; Eric Delaporte; Martine Peeters; Eitel Mpoudi-Ngole; Avelin Fobang Aghokeng
Journal:  Infect Genet Evol       Date:  2015-09-11       Impact factor: 3.342

8.  Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.

Authors:  Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger
Journal:  Lancet HIV       Date:  2015-06-16       Impact factor: 12.767

Review 9.  Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA.

Authors:  Neil T Parkin
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.500

10.  Validation of an ultrasensitive digital droplet PCR assay for HIV-2 plasma RNA quantification.

Authors:  Jean Ruelle; Vasilieios Yfantis; Armelle Duquenne; Patrick Goubau
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.